Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) has received a consensus recommendation of “Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $53.11.
Several equities research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 target price for the company. HC Wainwright lowered their target price on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and issued a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday, February 25th. Finally, Mizuho lowered their target price on shares of Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating for the company in a research note on Thursday, February 20th.
Get Our Latest Research Report on HRMY
Insiders Place Their Bets
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in HRMY. GSA Capital Partners LLP purchased a new position in Harmony Biosciences in the third quarter valued at $235,000. Quest Partners LLC increased its holdings in Harmony Biosciences by 137.6% in the third quarter. Quest Partners LLC now owns 35,723 shares of the company’s stock valued at $1,429,000 after buying an additional 20,689 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Harmony Biosciences in the third quarter valued at $359,000. Intech Investment Management LLC purchased a new position in Harmony Biosciences in the third quarter valued at $388,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock valued at $26,416,000 after buying an additional 140,690 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.
Harmony Biosciences Price Performance
NASDAQ HRMY opened at $34.32 on Thursday. The company has a market cap of $1.97 billion, a PE ratio of 16.27, a P/E/G ratio of 0.47 and a beta of 0.82. Harmony Biosciences has a 52-week low of $28.14 and a 52-week high of $41.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The firm’s 50 day moving average price is $36.40 and its 200-day moving average price is $35.62.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.11. The company had revenue of $201.30 million during the quarter, compared to the consensus estimate of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences’s revenue was up 19.5% compared to the same quarter last year. During the same period last year, the firm earned $0.45 earnings per share. Sell-side analysts forecast that Harmony Biosciences will post 2.43 EPS for the current fiscal year.
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Read More
- Five stocks we like better than Harmony Biosciences
- Election Stocks: How Elections Affect the Stock Market
- Can TikTok Stock Picks Really Make You Rich?
- What Are Growth Stocks and Investing in Them
- The “Quality” Rotation: Back to Basics Investing
- Upcoming IPO Stock Lockup Period, Explained
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.